Adaptive Biotechnologies Q4 2019 Earnings Report

Adaptive Biotechnologies reported a 41% increase in revenue for the fourth quarter of 2019, reaching $24.2 million, driven by growth in both sequencing and development revenue.

Key Takeaways

Adaptive Biotechnologies reported strong topline growth in commercial products and critical progress in advancing clinical product pipeline for Q4 2019. Total revenue reached $24.2 million, a 41% increase year-over-year. The company is focused on building commercial infrastructure and expanding R&D resources for immunoSEQ Dx and the Genentech alliance in 2020.

Revenue of $24.2 million, representing a 41% increase compared to the fourth quarter of 2018.

Clinical tests for clonoSEQ increased 66% compared to the fourth quarter 2018.

Initiated two additional pharma partnerships with AbbVie and Genentech to measure MRD using the clonoSEQ assay.

Delivered a data package to Genentech for the company’s first selected T-cell receptor candidate.

Total Revenue

$24.2M

Previous year: $17.2M

+40.8%

EPS

-$0.17

Previous year: -$0.125

+35.6%